Summary To investigate the role of ,B-tubulin isotype composition in resistance to paclitaxel, an anti-microtubule agent, human prostate carcinoma (DU-145) cells were intermittently exposed to increasing concentrations of paclitaxel. Cells that were selected and maintained at 10 nm paclitaxel (Pac-1 0) were fivefold resistant to the drug. Pac-1 0 cells accumulated radiolabelled paclitaxel to the same extent as DU-1 45 cells and were negative for MDR-1. Analysis of Pac-10 and DU-145 cells by flow cytometry showed similar cell cycle patterns. Immunofluorescent staining revealed an overall increase of a-and 1-tubulin levels in Pac-10 cells compared with DU-145 cells. Examination of 3-tubulin isotype composition revealed a significant increase in pill isotype in the resistant cells, both by immunofluorescence and by western blot analysis. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of the isotypes confirmed the increase observed for the ,,, by exhibiting ninefold higher ,,, mRNA levels and also showed fivefold increase of the Plv. transcript. In addition, analysis of paclitaxel-resistant cells that were selected at increasing levels of the drug (Pac 2, 4, 6, 8 and 10) exhibited a positive correlation between increasing P,,, levels and increasing resistance to paclitaxel. Increased expression of specific ,B-tubulin isotypes and subsequent incorporation into microtubules may alter cellular microtubule dynamics, providing a defence against the anti-microtubule effects of paclitaxel and other tubulin-binding drugs.
Paclitaxel has gained considerable attention in cancer therapy in recent years and is successfully used in treating a variety of tumours, including those of the breast, ovary and lung. In treatment of prostate cancer, paclitaxel is inactive when used as a single agent (Roth et al, 1993) . However, in combination with estramustine, another anti-microtubule agent, paclitaxel has significant activity against hormone refractory prostate cancer (Hudes et al, 1995) .
Despite its preclinical and clinical success, the exact mechanism of action of paclitaxel is not known. At low concentrations, paclitaxel blocks mitosis by kinetic stabilization of spindle microtubules (Jordan et al, 1993) . Paclitaxel differs from the other anti-microtubule agents such as vinblastine and colchicine by causing microtubule polymerization instead of depolymerization.
The c4p-tubulin heterodimer is the major component of microtubules. Most of the anti-microtubule agents, including paclitaxel, vinblastine, colchicine and estramustine bind to 3-tubulin. Paclitaxel binding sites on 3-tubulin were identified at the N-terminal 31 amino acids and at residues 217-231 of the protein . These two binding sites are part of the colchicine binding site and are highly conserved among species.
Both a-and ,-tubulins are encoded by multigene families and exist as several isotypes in cells. 3-Tubulin exists as six isotypes that are evolutionarily conserved across species and differ from each other predominantly at the carboxy terminus. Several in vitro studies reported that tubulin isotype composition affects microtubule assembly, drug sensitivity, drug binding and dynamics. For example, 0311-depleted tubulin assembles into microtubules at a faster rate than unfractionated tubulin (Banerjee et al, 1990 Pf31l-Tubulin also appears to be responsible for the slow-phase binding of colchicine. Lu and Luduena (1993) have shown that
Pffi-depleted microtubules are more sensitive to paclitaxel-induced polymerization than unfractionated tubulin. Previous studies from our laboratory have shown overexpression of m, and P,,1-tubulin isotypes in human prostate carcinoma cells as a result of resistance to estramustine (Ranganathan et al, 1996) . The clinical activity of estramustine and paclitaxel combination therapy of prostate cancer, despite the lack of activity of the single agents, prompted us to investigate the effect of paclitaxel on ,-tubulin isotypes. Thus, we have selected paclitaxel-resistant prostate carcinoma cells and examined their 3-tubulin isotype composition. Our results show that paclitaxel-resistant cells have altered P-tubulin isotypes, similar to estramustine-resistant cells.
MATERIALS AND METHODS Selection of non-MDR-1 mediated paclitaxel-resistant cell line
Our initial attempts to select paclitaxel-resistant cells by continuous exposure of DU-145 cells to the drug resulted in complete cell kill, even at concentrations as low as 2-3 nm. Thus, the following strategy was used to select a paclitaxel-resistant cell line. To select a non-MDR-l-mediated cell line, cells were exposed to paclitaxel with and without 10 gIM verapamil. DU-145 cells were treated with paclitaxel (Calbiochem, La Jolla, CA, USA) for 24 h, once a week, starting at 1 nM. After 2-3 weeks, the drug dose was escalated to the next level at 1 nm increments. Pac 2, 4, 6 and 8 cell lines represent cells selected at 2, 4, 6 and 8 nM paclitaxel respectively. Paclitaxel resistant (Pac-10) cells at 10 nm drug concentration were maintained by acute 24-h exposure to the drug, once a week. Cells were washed twice in phosphate-buffered saline (PBS) and placed in drug-free medium after the drug exposure.
Cytotoxicity assay
Cytotoxicity profiles of various anti-microtubule agents were determined by the method of Skehan et al (1990 (Zilfou and Smith, 1995) .
Flow cytometric cell cycle analysis
This was performed by standard methodology after propidium iodide staining of cellular DNA content. The percentage of cells in G, S and G2-M phases was calculated for DU-145 and Pac-10 cells (Vindelov et al, 1983 ).
3-Tubulin isotype staining by immunofluorescence DU-145 cells and Pac-10 cells were plated on glass coverslips and stained with P-tubulin antibodies, as described previously (Ranganathan et al, 1996) . PI,-, III-and Plv-antibodies were purchased from Biogenex Laboratories (San Ramon, CA, USA). General a-tubulin and ,-tubulin antibodies were purchased from Sigma Chemical and used at 1:200 dilution. Texas-red conjugated anti-mouse IgG (Molecular Probes, Eugene, OR, USA) was used as a secondary antibody at 1:200 dilution. Stained cells were scanned using the confocal microscopy system.
Protein analysis using western blots
Crude cytosolic lysates were prepared from DU-145 and Pac-10 cells, protein concentrations were estimated, run on 8% polyacrylamide gels and transferred onto PVDF membranes, as described previously (Ranganathan et al, 1996) . Blots were stained with isotype-specific and non-specific 3-tubulin antibodies. Similar analysis was performed using Pac 2, 4, 6 and 8 cell lines with P.,I-antibodies .
RT-PCR analysis of P-tubulin isotype transcripts and MDR-1 RNA was isolated from DU-145 and Pac-10 cell lines by a modified acid-guanidium lysis procedure (Chomczynski and Sacchi 1987) . Primers were chosen using the Primer Detective Program (Clontech, Palo Alto, CA, USA) and were synthesized by the DNA core facility at Fox Chase Cancer Center. P-Tubulin isotypespecific primers for the PI-, Pll-. 'In-and lv-isotypes were described in detail previously (Ranganathan et al, 1996) . The MDR-1 primers (nucleotides 1325-1347, 1502-1523 of the cDNA sequence) are specific for MDR-1 and span an intron to differentiate between amplified products derived from RNA and DNA. PCR products were analysed using agarose gel electrophoresis and quantified by scanning densitometry.
RESULTS
Resistance to paclitaxel and response to other anti-microtubule agents
As shown in Figure IA RT-PCR in DU-145 and paclitaxel resistant cells. RNA was isolated from both cell lines and MDR-1 transcript was amplified by using MDR-1 -specific primers. RT-PCR products were analysed using agarose gel electrophoresis. KB8-5, an MDR-1 expressing cell line, was used as a positive control increased levels of total a-and 3-tubulin protein were observed in the resistant cells (Figure 2 ). This was confirmed by western blot analysis and the increase for total a-and ,-tubulin levels was approximately threefold (data not shown). The 13-and PIisotypes were present at low levels in both cell lines. P11I-Isotype levels increased significantly in Pac-10 cells when compared with the parental DU-145 cells (Figure 2 ). This increase of PI,, was confirmed by Western blot (see Figure 4 ) and quantitated to be approximately fourfold elevated.
Analysis of P-tubulin isotypes by RT-PCR
Total RNA isolated from DU-145 and Pac-10 cells was used to amplify the P-tubulin isotype transcripts and the PCR products were analysed by agarose gel electrophoresis. The results were quantitated by using 18S RNA for normalization as described previously (Ranganathan et al, 1996) (Figure 3 ). These data show that the 1I1-transcript levels were ninefold higher in Pac-10 cells compared with DU-145 cells. In addition, there was a fivefold increase of 1-isotype in the resistant cells. This increase of , isotype could not be confirmed by western blot analysis because of lack of I13-specific antibodies. ,B-and Blvb-transcripts were the predominant isotypes in both cell lines and did not appear to change in Pac-10 cells as a result of resistance. The ,B1-isotype could not be detected in either of the cell lines under the PCR conditions (26 cycles). At 30 cycles, a faint band was seen with equal intensity in both cell lines (data not shown).
Correlation between paclitaxel resistance and ,1,,-levels To investigate further the relationship between paclitaxel resistance and the expression of P.-isotype, cells that were selected at different concentrations of the drug were analysed as shown in Figure 4 . Exposure to increasing levels of paclitaxel resulted in a gradient of increasing resistance to the drug. Western blot analysis of the cytosolic proteins from these cell lines showed a similar gradient of increasing Pm11-isotype protein concentrations from Pac-2 to Pac-10 cells (Figure 4, inset) .
DISCUSSION
The PII,-isotype differs significantly from the other ,-tubulin isotypes in its C-terminal amino acid composition (Sullivan, 1988) . Therefore, it may differ from the other isotypes in its microtubule assembly properties. Indeed, experiments performed with bovine brain tubulin in the presence of microtubule associated proteins (MAPs) have shown that the ,IB-depleted tubulin polymerizes at a faster rate than unfractionated tubulin (Banerjee et al, 1990) . Further study from the same laboratory has shown that the PIll-depleted tubulin was also more sensitive to paclitaxel-induced polymerization compared with unfractionated tubulin (Lu and Luduena, 1993) . The critical concentration of tubulin required for microtubule assembly in the presence of paclitaxel was approximately three times greater for the unfractionated bovine brain tubulin compared with the pI,,-depleted tubulin. In addition microtubules assembled from the I.B-depleted tubulin were shorter and more resistant to podophyllotoxin and colchine compared with the microtubules from unfractionated tubulin.
In earlier studies from our laboratory, we had observed increases of the 13m-and [3.-tubulin isotypes in human prostate carcinoma cells that had been made resistant to estramustine, a microtubuledepolymerizing agent (Ranganathan et al, 1996) . These cells were also partially cross-resistant to paclitaxel. In this study, we observed an increase in P. (Jordan et al, 1992; Derry et al, 1995; Dhamodharan et al, 1995) . Using purified 0-tubulin isotypes, Panda et al (1994) have shown that microtubule dynamics are regulated by the tubulin isotype composition.
Microtubules assembled from purified aBIn-isotype were more dynamic than microtubules made from a5xI-and a,rI3-isotypes or unfractionated tubulin. Moreover, microtubules composed of aP,B41-and aIlv-isotypes were four times less sensitive to inhibition of microtubule dynamics by paclitaxel (Derry et al, 1997 'i_ "W0) Haber et al (1995) have shown overexpression of PI3-isotype in a paclitaxel-resistant murine cell line that also overexpresses P-glycoprotein. In contrast, the paclitaxel-resistant DU-145 cells described in our study do not overexpress the MDR-1 gene product. Alterations in ,B-tubulin isotypes due to paclitaxel resistance have also been reported in other cell lines such as sarcoma, breast carcinoma and ovarian carcinoma (Giannakakou et al, 1996; Mallarino et al, 1996) . These studies indicate that the drug-induced change in isotype composition may be a general mechanism of resistance to paclitaxel and other agents that perturb microtubule dynamics.
Previously, we hypothesized that the favourable interaction of paclitaxel and estramustine in the treatment of patients with hormone refractory prostate cancer was based on the complementary but different targets within the microtubule, i.e. pacitaxel binding to Ptubulin and estramustine binding to microtubule-associated proteins and tubulin (Dahllof et al, 1993; Speicher et al, 1994; Laing et al, 1997) . The present results and our previous findings in estramustineresistant prostate cell lines suggest that resistance to paclitaxel and estramustine may share a common basis despite the differing binding sites on the microtubule. Regardless of how an agent interacts with the microtubule, the common effect of decreasing microtubule dynamics may explain the similar alteration in 3-tubulin isotype pattern in estramustine-and paclitaxel-resistant cell lines. Increasing microtubule dynamics by altering tubulin isotypes may constitute a general mechanism by which the cell can defend itself against the large number of natural compounds which inhibit microtubule dynamics. To further understand the significance of the [3m-and Pr isotypes in anti-microtubule drug therapy, transfection experiments using the P and [lv cDNAs are underway.
As single agents, estramustine (Hudes, 1997) and paclitaxel (Roth, 1993) are inactive in treatment of hormone refractory prostate cancer but given together these drugs show significant activity in preclinical (Speicher et al, 1992) and clinical studies (Hudes et al, 1995) . The mechanisms for greater than additive preclinical and clinical anti-tumour activity of paclitaxel/estramustine combination remains to be elucidated. Binding of one of these agents to the microtubules may alter the conformation of the target, thus facilitating binding of the second agent. The Cterminus of 3-tubulin peptide has been shown to be important in MAP binding and folding of the molecule (Cross et al, 1994; Fontalba et al, 1995) . Differing significantly from the other isotypes in its C terminus, the PI-isotope may also have distinct MAP-binding properties. Thus, it may be important for the synergistic activity of the paclitaxel/estramustine combination.
